Clinical trial
Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell…
NCT00008229 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00008229 |
|---|---|
| Title | Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma |
| Official title | A Phase III Multicenter, Randomized, Open-Label Trial Evaluating High Dose Melphalan Plus Holmium-166-DOTMP Versus High Dose Melphalan Alone When Given In Conjuction With Peripheral Blood Stem Cell Transplantation In Patients With Multiple Myeloma |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | filgrastim, melphalan, peripheral blood stem cell transplantation, holmium Ho 166 DOTMP |
| Start date | Aug 1, 2000 |
| Completion | Sep 1, 2001 |
| First posted | May 24, 2004 |
| Last update posted | Sep 21, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: